C Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Thank you Association for Molecular Pathology (AMP) for inviting me as the ‘Hematopathology Plenary Speaker’ at the AMP25 annual meeting and expo November 11-15, 2025 in Boston – to give a talk focused on precision medicine in myeloma!
During the meeting and expo, we had lots of great discussions on the needs and opportunities for prospective molecular profiling for every patient using WGS and immune profiling, future directions for blood-based MRD tracking, novel targeted immuno-PET imaging and other exciting strategies, evolving utilities of long-read sequencing as well as single cell sequencing, and much, much more.
The AMP23 meeting and expo served as a true melting pot for sharing of new ideas and initiation of future collaborations. Lots of smart and motivated molecular pathologists, researchers, clinicians, pharma/biotech/device companies, and more – meeting in-person for a few days – that is exactly what it takes to move the needle. The future of precision medicine equals to collaboration, transparency, and full speed forward!.”
Read more posts featuring C Ola Landgren on OncoDaily.
